BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/16/2022 1:07:50 PM | Browse: 535 | Download: 1489
 |
Received |
|
2021-09-14 02:19 |
|
Peer-Review Started |
|
2021-09-14 02:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-07 18:06 |
|
Revised |
|
2021-11-21 04:04 |
|
Second Decision |
|
2022-05-05 03:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-07 00:39 |
|
Articles in Press |
|
2022-05-07 00:39 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-25 08:28 |
|
Publish the Manuscript Online |
|
2022-06-16 13:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bonita Gu, Kavya Venkatesh, Astrid-Jane Williams, Watson Ng, Crispin Corte, Ali Gholamrezaei, Simon Ghaly, Wei Xuan, Sudarshan Paramsothy and Susan Connor |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bonita Gu, MD, Doctor, Doctor, South Western Sydney Clinical School, University of New South Wales, Goulburn St, Liverpool, Sydney 2170, New South Wales, Australia. bonita.gu@health.nsw.gov.au |
| Key Words |
Crohn’s disease; Perianal disorders; Biologics; Inflammatory bowel disease |
| Core Tip |
This multicentre retrospective study demonstrated a significant association between both infliximab and adalimumab trough levels with fistula healing, with higher levels associated with increased healing rates. Higher tertiles of both infliximab and adalimumab levels were associated with a higher proportion of patients achieving fistula healing. Fistula healing, defined as cessation of fistula drainage, is a clinically relevant endpoint that impacts on patient quality of life. Our results support dose-escalation of both infliximab and adalimumab in non-responders, targeting higher levels to achieve fistula healing prior to changing biologic therapy. Importantly, this study is the largest study to date assessing the relationship between adalimumab trough levels and clinical fistula healing. |
| Publish Date |
2022-06-16 13:07 |
| Citation |
Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W, Paramsothy S, Connor S. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease. World J Gastroenterol 2022; 28(23): 2597-2608 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i23/2597.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i23.2597 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
